LLY - Lilly and Incyte's baricitinib fails to meet main goal in late-stage COVID-19 trial

Eli Lilly (LLY) and Incyte (INCY) announced that their baricitinib treatment failed to meet the main goal in a late-stage trial testing the drug in hospitalized patients with COVID-19.The trial did not meet statistical significance on the primary endpoint, which was defined as a difference in the proportion of participants progressing to the first occurrence of non-invasive ventilation including high flow oxygen or invasive mechanical ventilation including extracorporeal membrane oxygenation ((ECMO)) or death by Day 28.The COV-BARRIER is the first global, randomized, double-blind, placebo-controlled study to assess baricitinib versus placebo in patients hospitalized with COVID-19 receiving SoC which could include corticosteroids, antimalarials, antivirals, and/or azithromycin.Patients were randomized 1:1 to baricitinib 4mg or placebo for up to 14 days or until discharge from the hospital.Baricitinib-treated patients were 2.7 per cent less likely than those receiving standard of care to progress to ventilation (non-invasive or mechanical) or death, a difference that was not

For further details see:

Lilly and Incyte's baricitinib fails to meet main goal in late-stage COVID-19 trial